Crescent Biopharma to Present at November Investor Conferences
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO) announced management will present at three investor conferences in November 2025: a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Nov 11, 2025 at 8:00 a.m. ET in Boston; a fireside chat at the Stifel 2025 Healthcare Conference on Nov 12, 2025 at 1:20 p.m. ET in New York; and a fireside chat at the Jefferies Global Healthcare Conference on Nov 19, 2025 at 9:30 a.m. GMT (4:30 a.m. ET) in London.
Each presentation will be livestreamed from Crescent's investor website and a replay will be accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CBIO
In the Nov 5 session, CBIO declined 0.08%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:
- Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Tuesday, November 11, 2025, at 8:00 a.m. ET in Boston.
- Stifel 2025 Healthcare Conference, fireside chat on Wednesday, November 12, 2025, at 1:20 p.m. ET in New York.
- Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 19, 2025, at 9:30 a.m. GMT (4:30 a.m. ET) in London.
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contact:
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
